HT
EDIT icon

Headlands Technologies’s Editas Medicine EDIT Stock Holding History

Headlands Technologies’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,853
Closed -$29.3K – 791
2026
Q1 		$29.3K Buy
+11,853
New +$25.1K ﹤0.01% 708
2025
Q4 		– Sell
-76,575
Closed -$266K – 712
2025
Q3 		$266K Buy
76,575
+69,391
+966% +$194K 0.02% 491
2025
Q2 		$15.8K Buy
+7,184
New +$11.8K ﹤0.01% 963
2024
Q2 		– Sell
-9,493
Closed -$70.4K – 1251
2024
Q1 		$70.4K Buy
9,493
+7,861
+482% +$65.3K 0.02% 621
2023
Q4 		$16.5K Buy
+1,632
New +$14.3K ﹤0.01% 693
2023
Q3 		– Sell
-5,758
Closed -$47.4K – 995
2023
Q2 		$47.4K Buy
+5,758
New +$50.2K 0.02% 479

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Headlands Technologies's EDIT Position: Q2 2026 in Review

Headlands Technologies sold out of Editas Medicine (EDIT) in Q2 2026, closing a stake of 11,853 shares — an estimated $29.3K sold.

Headlands Technologies first reported a position in EDIT in Q2 2023 and held it in 6 quarters. The position peaked at $266K in Q3 2025. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Headlands Technologies reported no remaining Editas Medicine position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 11,853 Editas Medicine shares in Q2 2026, an estimated $29.3K.
  • Headlands Technologies first reported a position in Editas Medicine in Q2 2023 and held it in 6 quarters.
  • Headlands Technologies's Editas Medicine position peaked at $266K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.